Kinesin-12, a Mitotic Microtubule-Associated Motor Protein, Impacts Axonal Growth, Navigation, and Branching

Mei Liu,1,2 Vidya C. Nadar,1 Frank Kozlowski,3 Marta Kozlowska,1 Wenqian Yu,1* and Peter W. Baas1*

1Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129, 2Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, Jiangsu 226001, China, and 3The Beatson Institute for Cancer Research, Glasgow G61 1BD, United Kingdom

Kinesin-12 (also called Kif15) is a mitotic motor protein that continues to be expressed in developing neurons. Depletion of kinesin-12 causes axons to grow faster, more than doubles the frequency of microtubule transport in both directions in the axon, prevents growth cones from turning properly, and enhances the invasion of microtubules into filopodia. These results are remarkably similar to those obtained in previous studies in which neurons were depleted of kinesin-5 (also called Eg5 or Kif11), another mitotic motor protein that continues to be expressed in developing neurons. However, there are also notable differences in the phenotypes obtained with depleting each of these motors. Depleting kinesin-12 decreases axonal branching and growth cone size, whereas inhibiting kinesin-5 increases these parameters. In addition, depleting kinesin-12 diminishes the appearance of growth-cone-like waves along the length of the axon, an effect not observed with depletion of kinesin-5. Finally, depletion of kinesin-12 abolishes the “waggling” behavior of microtubules that occurs as they assemble along actin bundles within filopodia, whereas inhibition of kinesin-5 does not. Interestingly, and perhaps relevant to these differences in phenotype, biochemistry studies, kinesin-12 coimmunoprecipitates with actin but kinesin-5 does not. Collectively, these findings support a scenario whereby kinesin-12 shares functions with kinesin-5 related to microtubule–microtubule interactions, but kinesin-12 has other functions not shared by kinesin-5 that are related to the ability of kinesin-12 to interact with actin.

Introduction

Decades ago, the microtubule array of the axon was viewed as a coherent slow-moving mass of polymers, transported throughout the life of the neuron, from the cell body toward the tip of the axon (Lasek, 1986). Today we know that only a small portion of the microtubules within the array undergoes transport at any given moment, and when this happens, the transport occurs rapidly, at the rate of known molecular motors proteins (Wang and Brown, 2002). Interestingly, only very short microtubules undergo transport, and the transport occurs in both directions. We have proposed that a variety of molecular motors generate forces on axonal microtubules, regardless of their length (Baas et al., 2006). In the case of the longer microtubules, these forces do not move the microtubules, but nevertheless are critical for determining whether the axon grows or retracts, and for regulating the proper turning of the growth cone. This scenario is reminiscent of the mitotic spindle, wherein even during phases of little movement, the microtubules are subjected to forces generated by a host of motor proteins (Walczak and Heald, 2008). Shifts in the balance of the motor-driven forces are instrumental for the progression of mitosis, and we posit that the same is true of various aspects of axonal morphogenesis.

In studies on cultured neurons, we have shown that inhibiting or depleting cytoplasmic dynein causes a reduction in the frequency of microtubule transport in the axon in the anterograde direction but not in the retrograde direction (He et al., 2005; Ahmad et al., 2006). The axon becomes more prone to retraction and the growth cones tend to stop at substrate borders rather than turn (Ahmad et al., 2000; Myers et al., 2006). When we deplete or inhibit kinesin-5, the frequency of short microtubule transport almost doubles in both directions, the axon grows faster and becomes less prone to retraction (Haque et al., 2004; Myers and Baas, 2007), and growth cones ignore cues that would otherwise cause them to turn (Nadar et al., 2008).

Kinesin-5, a homotetrameric motor also called Eg5 or Kif11, is best known for its role in mitosis, specifically in the separation of the half-spindles (Kashina et al., 1996; Scholey, 2009; Ferenz et al., 2010). Kinesin-12, a bipolar motor also called Kif15, is another mitotic motor that continues to be expressed in developing neurons (Buster et al., 2003). Although not as well studied as kinesin-5, kinesin-12 is believed to be important for maintaining half-spindle separation by opposing forces generated by other motors (Wittmann et al., 1998; Rogers et al., 2000). In fibroblasts, kinesin-12 alternately colocalizes with either microtubules or actin filaments, depending on the phase of the cell cycle (Buster et al., 2003). Given that many aspects of axonal morphogenesis involve the coordinated interplay between these two cytoskeletal elements, the potential ability of kinesin-12 to interact with both...
has compelling functional implications. Here, we conducted studies on the effects of kinesin-12 depletion on microtubule behaviors in the axon as well as axonal growth, navigation, and branching.

### Materials and Methods

**Generation of kinesin-5 and kinesin-12 antibodies.** The cDNAs encoding residues 801-991 of rKinesin-5 (GenBank No. XM_001060913) and 1146–1385 of kinesin-12 (GenBank No. NM_181635.2) were obtained with HF PCR using rat fetal brain cDNA (Clontech) as a template. The primers (rKinesin-5 tail-sense: 5'-ccg gaattc atg tgt ggt tca ctc agc aac-3' and antisense: 5'-ccg ctcgg ccg ctc tag ccg ctc ctc-3'; rKinesin-12 tail-sense: 5'-ccg gaattc atgg ccg ctc tag ccc tgg-3' and antisense: 5'-ccg ctcgg ctc tgg ttc ttc ttc ttc ttc ttc aac tgg-3') were synthesized by Integrated DNA Technologies. The cDNAs were restriction-digested with EcoRI and Xhol (NEB) and then cloned into PET-32a (Novagen). The sequences of the clones were confirmed by DNA sequencing performed by Genewiz. These constructs were used for protein expression in E. coli BL21 (DE3), and the corresponding His-rKinesin-5 tail and His-rKinesin-12 tail fusion proteins were purified using standard procedures. The rKinesin-12 tail antisera and rKinesin-5 tail antisera were generated by Cocalico Biological by immunizing at least two different rabbits in each case. The sera were affinity purified using IgG covalently bound to a HiTrap column (GE Healthcare Life Sciences). The affinity-purified antibodies were used at 1.0 μg/ml. The new rKinesin-12 antibody was used for Western blotting and immunoprecipitation, and the new rKinesin-5 antibody was used for Western blotting. For immunostaining of kinesin-12, we used our earlier antibody to kinesin-12 generated against the stalk domain (Buster et al., 2003), and for immunoprecipitation of kinesin-5, we used a commercially available kinesin-5 antibody (Abcam, ab37009).

**Western blotting.** Total protein from rat neuronal tissues (cerebral cortex, sympathetic ganglia) were extracted at different stages of development (embryonic day 19 (E19), postnatal day 1 (P1), P3, P7, P14, and adult from cortex; E18, E20, P1, P3, P7, P10, P14, and adult from sympathetic ganglia) using Celllytic microtubule cell Lysis Reagent (Sigma). The total protein was quantified using the BCA Protein Assay Kit (Pierce) and then adjusted to equal concentration and stored at −80°C in small aliquots. In some studies, protein samples were treated under nonreducing conditions as described previously (Kage et al., 2005). The Bio-Rad Mini-PROTEAN Tetra Cell system was used for electrophoretic separation of the protein samples as per the instructions from Bio-Rad Laboratories. Fifteen micrograms of protein samples were loaded in each lane and resolved using 7.5% SDS-PAGE for kinesin-12 and kinesin-5 and 10% SDS-PAGE for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (internal control). The gel was transferred onto nitrocellulose membranes (Bio-Rad, catalog number (Cat.) 162-0232), and the blots were blocked and then probed with rabbit anti-kinesin-12 tail polyclonal antibody at 4°C overnight. After washing, the blots were incubated with peroxidase-conjugated anti-rabbit IgG (Jackson ImmunoResearch). Membrane-bound peroxidase was visualized on Pierce CL-XPosure Film after enhancement with ECL Western Blotting Substrate (Pierce). Mouse monoclonal anti-GAPDH (Sigma) and the corresponding peroxidase-conjugated anti-mouse IgG (Jackson ImmunoResearch) were used.

**Immunocytochemistry.** Neuronal cultures were fixed at different times as described previously (Myers and Baas, 2007; Nadar et al., 2008). Cy3-conjugated anti-β-tubulin (1:800; Sigma, Cat. T4026) and rabbit polyclonal anti-cofilin antibody (1:2000; Abcam, Cat. ab42824) at 4°C for 14–16 h and then incubated in secondary antibodies (Cy3-conjugated goat anti-mouse IgG at 1:200, Cy3-conjugated goat anti-rabbit IgG, 1:800, Jackson ImmunoResearch; and Alexa Fluor 488 phalloidin, 1:40) for 1 h at 37°C. Fluorescence images were acquired as described previously (Hasaka et al., 2004). In one set of experiments, RFL-6 fibroblasts were immunostained for kinesin-12 as previously described (Buster et al., 2003). Immunostaining for the border assay is described below.

**Border assay.** We used a modification of the border assay used in previous studies to evaluate growth cone turning (Turner and Bridgman, 2005; Nadar et al., 2008). Sympathetic neuronal cultures were prepared and transfected with control siRNA and kinesin-12 siRNA and plated on laminin-coated (100 μg/ml) plastic dishes for 2 d. The coverslips for the border were prepared by adding 50 μl of laminin (25 μg/ml) in the center of poly-lysine-coated coverslips (Sigma, Cat. P9011; 0.1 mg/ml in borate buffer) and then incubated at 37°C for 3 h. Laminin was removed and the coverslips were rinsed with 50 μl of ddH2O three times before replating the cells. Each 45 μl of the cultured neurons treated with control or kinesin-12 siRNA were replated to the central region coated with lamin
Cloning, expression, purification of kinesin-5 and kinesin-12 motor domain (residues 43-399, named Kif15\textsubscript{43-399}) construct was prepared as described previously (Kaan et al., 2009). The cDNA coding for the human kinesin-12 motor domain (residues 43-399, named Kif15\textsubscript{43-399}) from Genescript was excised from the pUC57 vector and subsequently ligated into the expression vector pET-M20mod, and sequenced. The

Microtubule transport assay. The microtubule transport assay was performed as described previously (Hasaka et al., 2004). The neurons transfected with either control siRNA or kinesin-12 siRNA together with EGFP-tubulin were replated on poly-D-lysine-coated coverslips after 2 d as described above. The axons of EGFP-tubulin-transfected neurons were photobleached for 300 ms using the Mosaic System (Photronics). Time-lapse images were taken at 200–300 ms exposure at 2 s intervals for each axon for 5 min. Transport analyses included all microtubules observed to move continuously through the photobleached region during the imaging period. Transport frequencies were calculated for anterograde or retrograde direction by dividing the total number of movements by the total imaging time for individual movies.

Cloning, expression, purification of kinesin-5 and kinesin-12 motor domain, and studies on potential drug inhibition of kinesin-5 and kinesin-12 ATPase activities. Human kinesin-5 (Eg5\textsubscript{43-368}) was expressed in the insect cell line Sf21 using a baculovirus expression system. The purified protein was used in assays to determine the effect of a specific kinesin-5 inhibitor (Taub et al., 2009).

Kinesin-12 in the Axon

**Figure 2.** Effects of kinesin-12 depletion on the morphology of primary neurons from rat sympathetic ganglia. **A,** Western blot showing levels of kinesin-12 in cultured sympathetic neurons transfected with control siRNA and kinesin-12 siRNA for 2 and 4 d. **B,** Western blot showing levels of kinesin-12 in cultured sympathetic neurons shows significantly fewer branches and filopodia in neurons transfected with kinesin-12 siRNA compared to neurons transfected with control siRNA. Data are represented as mean ± SE, control siRNA = 106.3 ± 12.5 μm, n = 36; kinesin-12 siRNA = 207.4 ± 9.0 μm; n = 41, **p < 0.001. **C,** Quantification of axonal length in rat sympathetic neurons revealed significantly longer axons in neurons depleted of kinesin-12 compared to neurons transfected with control siRNA. Data are represented as mean ± SE, control siRNA = 106.3 ± 12.5 μm, n = 36; kinesin-12 siRNA = 207.4 ± 9.0 μm; n = 41, **p < 0.001. **D,** Quantification of axonal length in rat sympathetic neurons shows significantly fewer branches and filopodia in neurons transfected with kinesin-12 siRNA compared to neurons transfected with control siRNA. Data are represented as mean ± SD, axonal branches, control siRNA = 2.2 ± 0.4/100 μm, kinesin-12 siRNA = 1.2 ± 0.2/100 μm; actin filopodia, control siRNA = 14.2 ± 1.9/100 μm, kinesin-12 siRNA = 6.9 ± 0.9/100 μm; *p < 0.05, **p < 0.01.

**Figure 3.** Effects of depletion of kinesin-12 on the morphology of primary rat cortical neurons. **A,** Representative Western blot showing levels of kinesin-12 in cultured cortical neurons transfected with control siRNA or kinesin-12 siRNA for 1 and 3 d. GAPDH was used as a loading control. **B,** Representative pseudocolored fluorescence images of rat cortical neurons fluorescently stained for tubulin (blue) and F-actin (red). Scale bar, 25 μm. **C,** Quantification in rat cortical neurons revealed significantly longer axons in neurons transfected with kinesin-12 siRNA as compared to axons of neurons transfected with control siRNA. Data are represented as mean ± SE; control siRNA = 82.6 ± 4.4 μm, n = 45; kinesin-12 siRNA = 100.1 ± 6.5 μm, n = 47, **p < 0.05. **D,** Quantification in rat cortical neurons showed significantly fewer collateral branches, filopodia, and growth-cone-like waves in neurons transfected with kinesin-12 siRNA than in neurons transfected with control siRNA. Data are represented as mean ± SD; axonal branches, control siRNA = 4.9 ± 0.5/100 μm, kinesin-12 siRNA = 2.5 ± 0.4/100 μm; actin filopodia, control siRNA = 15.0 ± 1.0/100 μm, kinesin-12 siRNA = 8.5 ± 1.1/100 μm; actin- and cofilin-positive staining, control siRNA = 1.2 ± 0.2/100 μm, kinesin-12 siRNA = 0.4 ± 0.1/100 μm, **p < 0.01.
kinesin-12 expression was transformed into Codon+ E. coli cells. The expression and purification of kinesin-12 motor protein was performed as follows. Cells were lysed by sonication using eight cycles of 8 s of sonication, and subsequently centrifuged at 20,000 rpm for 1 h at 4°C. The supernatant (~100 ml) was applied to a 1 ml Histrap FF Ni-NTA column previously equilibrated in buffer A (50 mM PIPES, pH 7.0, 250 mM NaCl, 10 mM imidazole, 2 mM MgCl₂). The column was washed with 60 ml of buffer B (50 mM PIPES, pH 7.0, 250 mM NaCl, 40 mM imidazole, 2 mM MgCl₂), and kinesin-12 was eluted with a gradient from 40 to 500 mM imidazole. The protein-containing fractions were pooled and applied to a 16/60 desalting column (GE Healthcare) with buffer A (in the absence of any imidazole). The protein was incubated with 3 mM DTT and 0.05 mg of TEV/1 mg of kinesin-12 overnight at 4°C and subsequently passed over an additional desalting column using the same conditions. The protein was pooled and applied to a second 1 ml Ni-NTA column. Kinesin-12 elutes in the flow through, whereas noncleaved Trx-tagged kinesin-12, his-tagged TEV, and contaminations remain bound to the resin. The protein was concentrated to 2.5 ml and applied to a Superose 70 gel filtration column in buffer A supplemented with 1 mM DTT. After elution from the column kinesin-12 was concentrated to 2 mg/ml, supplemented with 1 mM Mg²⁺-ATP and used for ATPase activity assays without freezing. The inhibition of the basal and microtubule-stimulated ATPase activity of kinesin-5 and kinesin-12 by monastrol [or 0.1% DMSO was used as control. The comet trajectories were traced in these experiments using MetaMorph software (Universal Imaging)].

Coimmunoprecipitation. A commercially available Co-Immunoprecipitation Kit (Pierce, Cat. 23600) was used to investigate a potential interaction between kinesin-12 and actin. Briefly, RLF-6 cells were lysed in NP-40 Cell Lysis Buffer (containing Protease Inhibitor Cocktail, Pierce). Our new anti-rKinesin-12 tail antibody and a commercially available anti-actin antibody (Abcam, Cat. 3280) were immobilized in Antibody Coupling Resin and Control Resin, respectively, supplied in the kit. Coimmunoprecipitation and elution of coimmunoprecipitation complex, preparation of samples for SDS-PAGE were performed as per the instructions in the kit, respectively. Western blotting was used to determine the presence of actin and kinesin-12 in the coimmunoprecipitation complex. The kinesin-12 antibody and anti-actin antibody (Sigma, Cat. A2066) were used for immunoblotting. A commercially available kinesin-5 antibody (Abcam, ab37009) was used for coimmunoprecipitation assay of kinesin-5 and actin, and our anti-rKinesin-5 tail antibody was used to detect kinesin-5 on the Western Blots.

Statistics analysis and image processing. All data analyses, statistical comparisons, and graphs were generated using Excel (Microsoft) or Kaleidagraph. Data represent mean ± SEM of three or four separate experiments for each assay, and comparison was performed using a two-tailed t test or univariate ANOVA. For statistical analysis, the mean difference was considered to be significant at the 0.05 level. The final figure processing was performed with Photoshop 9.0 (Adobe).

Results

Developmental expression of kinesin-12

In a first set of studies, we wished to ascertain the pattern of expression of kinesin-12 in the CNS and peripheral nervous system (PNS). For this, we conducted quantitative Western blotting on homogenized tissues from rat cortex (CNS) and superior cervical ganglia (PNS) (Fig. 1). The predicted molecular weight of kinesin-12 is ~160 kDa. Our new polyclonal antibody against the tail domain of rat kinesin-12 produced a single band on Western blots that corresponded precisely to the predicted molecular weight. The band was diminished in cells treated with siRNA for kinesin-12 (Fig. 2A), confirming the identity of this band as kinesin-12. As shown in Figure 1, A and B, the levels of kinesin-12 are high in both cortex and ganglia at embryonic stages but then progressively diminish as development ensues. Beyond P14, the levels are barely detectable. When the samples were treated under nonreducing conditions, the band appeared at twice the molecular weight, which is consistent with the prediction that kinesin-12 exists as a dimer in the cytoplasm of these tissues (Fig. 1A, arrowhead).
were released from the substrate and replated at lower density on glass-bottomed 35 mm culture dishes and allowed to grow axons anew for 24 h. With regard to PNS sympathetic neuronal cultures, the morphology of the neurons depleted of kinesin-12 was markedly different from controls, with the kinesin-12-depleted neurons displaying notably longer axons (Fig. 2B–D). The axons of kinesin-12-depleted neurons were also less branched and displayed fewer filopodia (Fig. 2E). Quantification of the morphological changes shown in Figure 2, D and E, revealed an almost 95.3% increase in axonal length (see figure legend for statistics), and the axonal branches and filopodia were 66.3% and 51.3% diminished, relative to the control, respectively (see figure legend for statistics). The greater length of the axons is reminiscent of results obtained with inhibition or depletion of kinesin-5 (Haque et al., 2004; Yoon et al., 2005; Myers and Baas, 2007), but the effect on branching is the opposite.

Depletion of kinesin-12 also impacts CNS neuronal morphology

In our earlier work, we reported evidence suggesting that kinesin-12 may be able to interact with actin filaments (Buster et al., 2003). For this reason, we also used CNS cortical neurons, mainly because they undergo additional actin-dependent morphological behaviors not observed with the sympathetic neurons in culture. Specifically, they generate collateral branches along their length, a process that requires the interplay between microtubules and actin filaments (Dent and Kalil, 2001), and they generate growth-cone-like waves that move anterogradely down the axon’s length (Ruthel and Banker, 1999; Flynn et al., 2009; Tint et al., 2009). [The branches from the axons of sympathetic neurons result almost entirely from growth cone bifurcation, and no such waves are seen moving along their axons.] The cortical neurons were transfected with the kinesin-12 siRNA for 3 d, after which the level of kinesin-12 was decreased by almost 90% (Fig. 3A). In cortical neurons depleted of kinesin-12, we observed a 21.2% increase in axonal length relative to controls (see figure legend for statistics), which is notable but less dramatic than the effect with cortical neurons depleted of kinesin-12 (Buster et al., 2003). Since then, we found that inhibiting kinesin-5 actually elicited the effects on the microtubule array that we might have predicted of inhibiting kinesin-5 (Myers and Baas, 2007; Nadar et al., 2008). Within the axon, only very short microtubules undergo rapid concerted transport, with about two-thirds of the movements in the anterograde direction and one-third in the retrograde direction (Wang et al., 2009).

Depletion of kinesin-12 inhibits growth cone turning

To test whether kinesin-12 is involved in growth cone turning, we used the “border assay,” which uses a glass coverslip with a sharp border between a laminin-coated side and a poly-ribo-lysin-coated side (Turney and Bridgman, 2005; Nadar et al., 2008). When neurons are plated on the laminin side, growth cones normally turn when they reach the border. Indeed, almost all axons turned at the border in the case of control neurons (Fig. 4A). However, very few axons of the kinesin-12-depleted neurons turned (Fig. 4B). Instead, the growth cones ignored the border, crossed it, and continued growing on the polylysine side. This effect was quantified by measuring the fluorescence for the immunostained axonal microtubules on each side of the border (Fig. 4C). The ratio of microtubule fluorescence per unit pixel area of axons that crossed the border and axons that turned at the border showed 480% increase in kinesin-12-depleted neurons as compared to the control neurons (see figure legend for statistics). Notably, this effect is essentially the same as observed in our earlier study on neurons in which we depleted or inhibited kinesin-5 in these neurons (Nadar et al., 2008).

Depletion of kinesin-12 increases frequency of microtubule transport in the axon

The earliest speculations on the function of kinesin-12 in the mitotic spindle were that kinesin-12 keeps the half-spindles separated by opposing the forces generated by other motors that would otherwise draw the half-spindles together (Wittmann et al., 1998; Rogers et al., 2000). On this basis, we speculated that kinesin-12 might similarly oppose microtubule movements by other motors in the axon (Buster et al., 2003). Since then, we found that inhibiting kinesin-5 actually elicited the effects on the microtubule array that we might have predicted of inhibiting kinesin-12 (Myers and Baas, 2007; Nadar et al., 2008). Within the axon, only very short microtubules undergo rapid concerted transport, with about two-thirds of the movements in the anterograde direction and one-third in the retrograde direction (Wang et al., 2009).
and Brown, 2002; Hasaka et al., 2004; He et al., 2005). When kinesin-5 was inhibited or depleted, the frequency of these transport events increased (in both directions) (Myers and Baas, 2007). There was no change in the rate of transport of individual microtubules.

Here, we used the same live-cell imaging paradigm to study microtubule transport in the axons of kinesin-12-depleted rat sympathetic neurons. The method involves expression in the neurons of EGFP-tubulin, followed by photobleaching a 40 μm region along the axon’s length. Then, fluorescent microtubules from flanking unbleached regions are observed to move through the bleached zone (Fig. 5A). As with the kinesin-5 results, there was no change in the rate of the movements, but there were marked elevations in the frequency of movements in both directions. With kinesin-12 depletion, there were 266% and 187% increases in the anterograde and retrograde directions, respectively (Fig. 5B; see legend for statistics). This result is similar but not identical to the result with kinesin-5 inhibition, in which we observed an ~79.5% increase in the anterograde direction and a 72.1% increase in the retrograde direction (Myers and Baas, 2007). Thus, it would appear that both motors are important for limiting the number of short microtubules moving within the axon.

Kinesin-12 and kinesin-5 function independently of one another

Although we have used kinesin-5 siRNA in past studies, a great deal of our work on this motor has used the allosteric kinesin-5 inhibitor called monastrol. Notably, kinesin-5 depletion by siRNA results in essentially the same impact as monastrol treatment on microtubule transport and distribution, the same phenotypic effects on axonal length and morphology, and the same impact on growth cone turning (Haque et al., 2004; Myers and Baas, 2007; Nadar et al., 2008). Given that kinesin-12 does not share the unique large loop L5 region of kinesin-5 targeted by the drug, we would not have predicted these drugs to inhibit kinesin-12. However, the remarkable similarities between the phenotypes and especially the effects on microtubules in monastrol-treated cultures and kinesin-12-depleted cultures led us to wonder whether monastrol might inhibit kinesin-12 as well as kinesin-5. Curiously, although monastrol has been tested and found not to inhibit a wide array of other kinesins (DeBonis et al., 2003; Tcherenkiuk et al., 2010), it has never been tested on kinesin-12. So, here, we used the same approach as has been used in the past to test whether known kinesin-5 inhibitors also inhibit kinesin-12 (Mayer et al., 1999). This was done by measuring the inhibition of the basal and microtubule-stimulated ATPase activities of kinesin-12 in the presence of increasing concentrations of monastrol (and also STLC, another anti-kinesin-5 drug that is currently more often used than monastrol by many investigators because it is potent in the low nanomolar range). Kinesin-5 was used as a positive control. Whereas monastrol inhibits kinesin-5 activities with IC50 values of 7.7 ± 1.1 μM and 31.2 ± 4.4 μM for the basal and microtubule-stimulated ATPase activities, respectively, kinesin-12 was not inhibited at concentrations up to 100 μM, indicating the specificity of monastrol for kinesin-5 (Fig. 6A,B). This result confirmed that kinesin-12 is not inhibited by monastrol, even when used at the high concentrations (e.g., 100 μM) in our cell biological studies. STLC was also shown in our study not to inhibit kinesin-12 (Fig. 6C,D).

Interestingly, as we were conducting these studies on neurons, two articles were published indicating overlapping phenotypes of kinesin-12 and kinesin-5 inhibition during mitosis (Tanenbaum et al., 2009; Vanneste et al., 2009). It was reported that cells depleted of kinesin-5 can recover from their monastrol phenotype if kinesin-12 is overexpressed (Tanenbaum et al., 2009). Thus, apparently the functions of these two motors are similar enough that, at least in some circumstances, one can substitute for the other. We wondered whether the two motors in neurons might produce such similar phenotypes, when inhibited together, because they somehow depend on each other. However, arguing against this, when we combined monastrol treatment with kinesin-12 inhibition, we found that axons grew faster than with either treatment alone. As shown in Figure 6E, the elevations above control levels were roughly additive, which suggests that
Depletion of kinesin-12 impacts microtubule behaviors in the growth cone as well as the size of the growth cone

The reason why kinesin-5 inhibition causes growth cones to fail to turn is readily observed if the neurons are transfected to express EGFP-EB3. EB3 is a microtubule end-binding protein that associates with the plus-end of the microtubule during bouts of assembly, and hence the GFP protein reveals microtubule behaviors in live-cell imaging in the form of fluorescent “comets” at the plus ends of the assembling microtubules (Stepanova et al., 2003). When kinesin-5 is inhibited, there is a notable increase in the numbers of comets entering the peripheral domain of the growth cone and an increase in the rate of the comets as well (Nadar et al., 2008). As shown in Figure 7A–C, the growth cones of kinesin-12-depleted neurons show qualitatively the same effect. Quantitative analysis of the number of EB3 comets that enter the filopodia of growth cones per minute showed an increase of 52% in the case of neurons depleted of kinesin-12 compared to control (Fig. 7C, see figure legend for details). Depletion of kinesin-12 also resulted in a 39% increase in the velocity of EB3 comets in the axonal shaft and a 36% increase in the velocity in the filopodia (Fig. 7D, see figure legend for statistics).

More detailed analyses on the EGFP-EB3 comets revealed a difference in microtubule behaviors in growth cones of neurons depleted of kinesin-12 versus neurons treated with monastrol. In control neurons, the microtubules show a subtle but consistent “waggling” behavior in filopodia, which presumably reflects the retrograde flow of the actin bundle along which microtubule assembly. This effect was obliterated with the depletion of kinesin-12, but not with the inhibition of kinesin-5 (shown in
Depletion of kinesin-12 has an effect on growth cone size opposite to that of inhibition of kinesin-5. **A–D**, Representative fluorescence images of growth cones stained with Alexa Fluor 488-Phalloidin to reveal actin filaments. Images were inverted to show the morphologies more clearly. **A**, Control siRNA and DMSO; **B**, kinesin-12 siRNA and DMSO; **C**, control siRNA and monastrol; **D**, kinesin-12 siRNA and monastrol. Scale bar, 10 µm. **E**, Quantification of growth cone size of cultured sympathetic neurons revealed that depletion of kinesin-12 and inhibition of kinesin-5 had opposite effects. Data are represented as mean ± SE, control siRNA/DMSO = 24.3 ± 4.3 µm², n = 34; kinesin-12 siRNA/DMSO = 13.8 ± 2.0 µm², n = 36; control siRNA/monastrol = 37.2 ± 3.9 µm², n = 45; kinesin-12 siRNA/monastrol = 21.6 ± 2.4 µm², n = 34; *p < 0.05.

With regard to growth cone size, we observed opposite effects from depleting kinesin-12 and inhibiting kinesin-5. Compared to the control, depletion of kinesin-12 showed 43.2% decrease of mean size of growth cone, while inhibition of kinesin-5 produced a 53.1% increase, as shown in Figure 8A–E. There was no significant difference compared to control when neurons were treated with kinesin-12 siRNA combined with monastrol [although the morphology is somewhat different; with both motors suppressed, the growth cone looks more flattened (Fig. 8D)]. These effects may be related to kinesin-5’s microtubule cross-linking properties relative to kinesin-12, given that more tightly bundled microtubules would presumably lead to more compact growth cones, and to kinesin-12’s potential ability to interact with actin filaments (see next section), a major determinant of growth cone shape.

Kinesin-12 coimmunoprecipitates with actin, but kinesin-5 does not

The observed differences in the phenotypes of neurons in which we depleted kinesin-12 or inhibited kinesin-5 are consistent with a scenario whereby the unique effects of kinesin-12 result from its ability to interact with actin. Our evidence for this was the fact that in RFL-6 rat fibroblasts, the staining with an antibody for kinesin-12 colocalized mainly with actin bundles in interphase as well as with the cleavage furrow in telophase (Buster et al., 2003). We noted that kinesin-12 has a myosin-like sequence within its stalk region, and posited that it is perhaps through this domain that kinesin-12 elicits such an interaction. However, other possibilities exist for the actin-like immunostain pattern of kinesin-12 in these fibroblasts. The antibody that we found most effective for immunostaining was generated against the stalk domain of kinesin-12, and produced an extra band of unknown identity on Western blots (Buster et al., 2003). Given that the molecular weight of the extra band is consistent with myosins, we wondered whether the actin-like staining pattern at some phases of the cell cycle might relate to cross-reactivity of the antibody with myosins rather than a bona fide colocalization of kinesin-12 with actin. We have now sequenced this extra band and found that it indeed corresponds to MYH9 and MYH10 (both of which are myosin-II family members). To ascertain whether any of the actin-like staining is actually due to kinesin-12, we depleted kinesin-12 from the fibroblasts using siRNA and then immunostained the cells with the same antibody. We found that the actin-like staining was either completely eliminated from cells or markedly reduced. Any remaining filamentous staining was typically observed in the more peripheral regions of the cells. For quantification, we scored cells as positive if they had any detectable filamentous quality to their staining, or negative if the staining was entirely diffuse in nature. Thus, by these criteria (which err on the side of caution, given that we scored cells as positive even if the filamentous staining was down substantially but not completely eliminated), the loss was ~57% (*p < 0.0001; χ² test) (Fig. 9A–C). These results indicate that while some of the actin colocalization is not due to kinesin-12, much of it is. Consistent with this, previous studies on kinesin-12 immunostaining in other species (Rogers et al., 2000) using different antibodies also reported the localization of kinesin-12 to the telophase cleavage furrow.

We next wished to further test for a potential interaction between kinesin-12 and actin, using a biochemical approach. For this, we used our new rKinesin-12 antibody, which is raised against the tail domain and hence does not recognize myosins.

---

**Figure 8.** Depletion of kinesin-12 has an effect on growth cone size opposite to that of inhibition of kinesin-5. **A–D**, Representative fluorescence images of growth cones stained with Alexa Fluor 488-Phalloidin to reveal actin filaments. Images were inverted to show the morphologies more clearly. **A**, Control siRNA and DMSO; **B**, kinesin-12 siRNA and DMSO; **C**, control siRNA and monastrol; **D**, kinesin-12 siRNA and monastrol. Scale bar, 10 µm. **E**, Quantification of growth cone size of cultured sympathetic neurons revealed that depletion of kinesin-12 and inhibition of kinesin-5 had opposite effects. Data are represented as mean ± SE, control siRNA/DMSO = 24.3 ± 4.3 µm², n = 34; kinesin-12 siRNA/DMSO = 13.8 ± 2.0 µm², n = 36; control siRNA/monastrol = 37.2 ± 3.9 µm², n = 45; kinesin-12 siRNA/monastrol = 21.6 ± 2.4 µm², n = 34; *p < 0.05.
This antibody is not optimal for immunostaining, but is quite specific to kinesin-12, as it produces only one band on Western blots. We found that kinesin-12 coimmunoprecipitates with actin in a widely used and reliable coimmunoprecipitation assay (Fig. 9D), but that kinesin-5 does not (Fig. 9E). This result confirms that kinesin-12, at least under certain circumstances, can interact with actin, although the question remains as to whether this interaction is direct or indirect.

Discussion

Our original goal in studying mitotic kinesins in neurons was to identify the motors that transport microtubules in axons and dendrites (Baas, 1999). With regard to the axon, our hypothesis has been that cytoplasmic dynein and a small number of mitotic kinesins share this responsibility (Baas et al., 2006). Given that depletion of cytoplasmic dynein reduces the anterograde movements by half with no apparent reduction in the retrograde movements (He et al., 2005), we concluded that there is a need for kinesins to participate in the transport of microtubules in both directions. We have now studied kinesin-5 and kinesin-12. Interestingly, depletion or inhibition of these motors has no detrimental effect on the frequency of short microtubule transport (Myers and Baas, 2007), but instead, produces a marked increase in transport frequency. Thus, our hypothesis regarding these motors and their role in the transport of axonal microtubules needs to be revised. One possibility is that cytoplasmic dynein is actually responsible for a greater share of the burden than our studies thus far have suggested, given that we have generally depleted only ~85% of the dynein in these experiments. Another possibility is that some of the nonmitotic kinesins may be able to participate in the transport of microtubules. Consistent with this, recent studies indicate that kinesin-1 is able to transport microtubules in other cell types (Jolly et al., 2010).

Since our original finding that inhibition of kinesin-5 enhances bidirectional microtubule transport in the axon (Myers and Baas, 2007), the underlying mechanistic explanation for this has been elusive. Kinesin-5 is a homotetramer with four motor domains projected outward (Kashina et al., 1996), thus enabling it to move along two neighboring microtubules toward their plus ends (Kapitein et al., 2008). If the microtubules are oppositely oriented, the result would be to move them apart. If the microtubules have the same orientation, the homotetramer would presumably move along both of them, perhaps helping to align them, but not immobilizing them. In the case of the bipolar kinesin-12, less is known about how it generates forces between microtubules, but it apparently works in conjunction with a microtubule-binding protein called TPX2 to mimic the manner by which kinesin-5 functions (Tannebaum et al., 2009). This is feasible in neurons, given that TPX2 has been identified in the cytoplasm of neurons (Mori et al., 2009). Both motors can presumably cross-link microtubules, but to cross-link them does not mean to immobilize them, unless the motor is in a rigor state, and there is no real precedent for this occurring in living cells, to the best of our knowledge. Now that we know that kinesin-12 imposes an even more potent effect to diminish short microtubule transport in the developing axon than kinesin-5, the question becomes more urgent as to how exactly these two very different motors are doing this.

A potential clue comes from recent studies in which we quantified microtubule transport in the axon after overexpressing spastin, a potent microtubule-severing protein (Qiang et al., 2010). This regime resulted in higher numbers of short microtubules throughout the neuron. The frequency of short microtubules projections outward (Kashina et al., 1996), thus enabling it to move along two neighboring microtubules toward their plus ends. The forces exerted by cytoplasmic dynein impose forces along the axonal shaft that compress the microtubules in both directions, depending on the orientation of the motor. The kinesin-12 and kinesin-5 forces are stronger than the kinesin-5 forces during development (depicted here by the different thicknesses of the force arrows), but kinesin-12 levels diminish more as development ensues than do kinesin-5 levels. The kinesin-12 and kinesin-5 forces are stronger in the cell body than in the axon itself, thereby regulating the entry of short microtubules into the axons. The forces exerted by cytoplasmic dynein are more uniform throughout the cell body and axons.

- Figure 9. Evidence for an interaction of kinesin-12 but not kinesin-5 with actin. A–C, Experiment in which the kinesin-12 antibody we previously used for immunostaining RFL-6 fibroblasts (Buster et al., 2003) was used to immunostain control cultures (A) as well as cultures that had been depleted of kinesin-12 by siRNA (B). Scale bar, 100 μm. The staining typically shows a strong filamentous pattern in control interphase cells (A), with the filament bundles corresponding to actin filaments (see Buster et al. (2003) for double-labeling results). In kinesin-12-depleted cells, there is still fluorescence, but it is typically dimmer than controls, and the intense filamentous staining is markedly reduced or completely eliminated. The white arrow in B indicates a cell depleted of kinesin-12 with siRNA that shows some filamentous staining near the periphery but far less so in other regions of the cell. The cells denoted by asterisks show no filamentous quality to the staining. Data are represented (in C) as percentage of cells displaying any observable filamentous staining, even if substantially reduced compared to control; control siRNA: 73%; n = 380; kinesin-12 siRNA: 16%; n = 266; p < 0.0001 (χ² test). D, Western blot showing the positive results of the coimmunoprecipitation assay for kinesin-12 and actin. E, Western blot showing the negative results of coimmunoprecipitation of kinesin-5.

- Figure 10. A model for how forces imposed by various molecular motors act on the microtubule array of the axon. We posit a model wherein cytoplasmic dynein imposes forces that pull on the microtubules in an anterograde direction, while kinesin-5 and kinesin-12 impose forces that pull in the retrograde direction. Actomyosin forces push back on the microtubules in the growth cone and also impose forces along the axonal shaft that compress the microtubules toward the cell body. A variety of other kinesins impose forces on the microtubules in both directions, depending on the orientation of the motor. Kinesin-12 forces are stronger than kinesin-5 forces during development (depicted here by the different thicknesses of the force arrows), but kinesin-12 levels diminish more as development ensues than do kinesin-5 levels. The kinesin-12 and kinesin-5 forces are stronger in the cell body than in the axon itself, thereby regulating the entry of short microtubules into the axons. The forces exerted by cytoplasmic dynein are more uniform throughout the cell body and axons.
bule transport in the axon was notably increased in both directions and about equally in both directions. These results suggest that it may not be motors acting as brakes in the axon that controls the number of short microtubules in transit, but rather it may be the number of short microtubules in the axon that determines the frequency of observable transport events. Thus under normal conditions, it may be that kinesin-5 and kinesin-12 are imposing a limit on the number of short microtubules that can transit into the axon from the cell body, rather than serving as brakes within the axon itself. Mechanistically, this might make more sense because microtubules are situated in all manner of configurations in the cell body (Yu et al., 2001), so there are a number of different possibilities for how forces generated by kinesin-5 and kinesin-12 could work in opposition to cytoplasmic dynein to limit the number of microtubules than can move into the axon.

A marked increase in the vitality of short microtubule transport could be a significant factor in why suppressing either kinesin-5 or kinesin-12 causes axons to grow faster. However, the profound phenotypes we observed when these motors are depleted or inhibited may be more attributable to their effects on the longer stationary microtubules in the axon. Assuming kinesin-5 and kinesin-12 can be transiently immobilized against other structures, long microtubules interacting with their motor domains would be pulled toward the cell body. Taking into account our previous findings on other motors, cytoplasmic dynein would simultaneously pull on the microtubules in the opposite direction (Myers et al., 2006). In order for the axon not to retract, the sum of these forces (and perhaps forces generated by other kinesins) must be greater than the contractile forces generated by the actomyosin system along the axonal shaft. If this is the case, the axon grows. If it is not the case, the axon retracts. Removing either kinesin-5 or kinesin-12 shifts the balance toward growth, which is why the axon becomes longer when either of these motors is depleted or inhibited. This scenario (shown schematically in Fig. 10) can also explain the effects on the growth cone, wherein the actomyosin forces are pushing the microtubules backward toward the axonal shaft, while dynein-driven forces are pulling the microtubules forward from the axonal shaft into the peripheral domain of the growth cone. Kinesin-5 and kinesin-12 both oppose the forces of cytoplasmic dynein to enable microtubules to enter the peripheral domain and invade filopodia. The forces would have to be spatially regulated (Nadar et al., 2008), to direct microtubules into certain filopodia but not others during normal growth cone turning. If either kinesin-5 or kinesin-12 is inhibited, microtubules enter the filopodia without proper spatial control, and the growth cone fails to turn properly.

Overlapping functions for kinesin-5 and kinesin-12 in the neuron are consistent with recent reports of kinesin-12 being able to compensate for loss of kinesin-5 during mitosis (Tanenbaum et al., 2009). However, the phenotypes observed when one or the other motor is suppressed in neurons are not identical in every way. For example, suppression of kinesin-5 increases axonal branching, while suppression of kinesin-12 decreases axonal branching. Considering only microtubule–microtubule interactions, kinesin-12 should suppress axonal branching, as does kinesin-5, by pulling the microtubules backward. The unique feature of kinesin-12 that might account for the reverse phenotype is the potential for kinesin-12 to interact with the actin cytoskeleton. We previously reported that kinesin-12 has a myosin-like domain in its stalk region (Buster et al., 2003), and this might explain its positive impact on axonal branching, given that axonal branch formation requires interactions between microtubules and filamentous actin (Dent and Kalil, 2001). In support of this idea, at least one antibody to kinesin-12 produces staining that colocalizes with actin filaments at certain stages of the cell cycle in fibroblasts, although this result needs to be interpreted with caution because the antibody also recognizes myosin-II family members (but also see experiments in Fig. 9A–C). Additional support for an interaction with actin comes from our finding that kinesin-12 coimmunoprecipitates with actin, and depletion of kinesin-12 from neurons results in smaller growth cones and fewer growth-cone-like waves along the axon. Finally, detailed analyses of microtubules assembling along the actin bundle in filopodia suggest that the microtubule is normally linked to the actin bundle (as demonstrated by a subtle “waggling” effect on the microtubule’s trajectory) but loses this link- age in the absence of kinesin-12 (Fig. 7F). None of these observations are true of kinesin-5.

To the best of our knowledge, there are just a few examples in the literature of kinesins interacting with actin. A plant-specific member of the kinesin-14 family in cotton has been shown to strongly interact with actin (Xu et al., 2009), and the CHO1 variant of the MKLP1 (kinesin-6) family has a domain that interacts with actin (Kuriyama et al., 2002). Other kinesins may interact with actin indirectly, through common binding partners (Medina et al., 2008). Given that kinesin-12 has a myosin-like domain, its interaction with actin could be direct, but it is worth noting that we have never observed an immunostain pattern in neurons with any kinesin-12 antibody that suggests an actin-like distribution. Thus, whatever the interaction may be, direct or indirect, we would surmise that it is tightly regulated and not “always on.” The fact that kinesin-12 is expressed early in neuronal development but not later is consistent with a role for kinesin-12 in actin-based structures and events that are especially predominant during development, such as branch formation, growth cone form and function, and the propagation of growth-cone-like waves within some axons.

In conclusion, we have reported new information on a little studied but functionally powerful molecular motor in developing axons. In addition to providing insights into kinesin-12 itself, the results of these studies challenge some of our own previous views on how molecular motors impact both short and long microtubules in the axon.

References


